Preferred Label : Allogeneic Anti-BCMA CAR-transduced T-cells ALLO-715;
NCIt synonyms : ALLO-715 Cells; BCMA Allogeneic CAR T Cells ALLO-715; ALLOCar T ALLO-715;
NCIt related terms : ALLO-715;
NCIt definition : A preparation of allogeneic, 'off-the-shelf' (OTS), universal transcription activator-like
effector nuclease (TALEN)-engineered, gene-edited T-lymphocytes that have been transduced
with a vector expressing a chimeric antigen receptor (CAR) containing a single chain
variable fragment (scFv) derived from a monoclonal antibody specific for the human
tumor-associated antigen (TAA) B-cell maturation antigen (BCMA; tumor necrosis factor
receptor superfamily member 17; TNFRSF17), with potential immunostimulating and antineoplastic
activities. Using TALEN technology, the T-cell receptor (TCR) alpha chain (TRAC) and
CD52 genes are deleted from the CAR T-cells. Upon administration, the allogeneic anti-BCMA
CAR-transduced T-cells ALLO-715 specifically recognize and induce selective toxicity
in BCMA-expressing tumor cells. BCMA, a receptor for both a proliferation-inducing
ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis
factor receptor superfamily (TNFRSF). BCMA is found on the surfaces of plasma cells,
is overexpressed on malignant plasma cells and plays a key role in plasma cell proliferation
and survival. Deletion of the CD52 gene makes the modified donor T-cells resistant
to an anti-CD52 monoclonal antibody treatment, that is used during lymphodepletion.
The knockout of TRAC eliminates TCR expression and is intended to abrogate the potential
induction of graft-versus-host disease (GvHD) by the donor T-cells. The donor-derived,
gene-edited CAR T cells have reduced production times and have increased availability
when compared to autologous CAR-T cells, which use the patient's own cells and are
produced on an individual basis. In addition, if the ALLO-715 cells cause unacceptable
side effects, the incorporated CD20-based off-switch permits selective depletion of
the ALLO-715 cells when the anti-CD20 monoclonal antibody rituximab is administered.;
UNII : Q137JC2CLV;
Molecule name : ALLO 715; ALLO-715;
NCI Metathesaurus CUI : CL979064;
Origin ID : C165779;
UMLS CUI : C5237454;
Semantic type(s)
- Cell [UMLS semantic type]
- concept_is_in_subset
- has_target
